Skip to main content
. 2021 Aug 6;29(9):2794–2805. doi: 10.1016/j.ymthe.2021.08.001

Table 2.

The incidence of ADRs associated with COVID-19 vaccines via meta-analysis

Group Pain Swelling Fever Fatigue Chills Muscle pain (myalgia) Joint pain (arthralgia) Headache
Dose 1 (subgroups by vaccine type, n = 23,505)

Protein subunit (n = 26) 0.3846 (0.2210–0.5793) 0.0000 (0.0000–1.0000) 0.0000 (0.0000–1.0000) 0.3077 (0.1620–0.5055) 0.0000 (0.0000–1.0000) 0.2308 (0.1075–0.4276) 0.0385 (0.0054–0.2279) 0.2308 (0.1075–0.4276)
RNA-based vaccine (n = 23,351) 0.8097 (0.7667–0.8463) 0.0624 (0.0594–0.0656) 0.0145 (0.0059–0.0350) 0.3927 (0.3630–0.4233) 0.0936 (0.0785–0.1112) 0.2029 (0.1726–0.2370) 0.1303 (0.0920–0.1813) 0.3366 (0.3218–0.3517)
Viral vector (non-replicating; n = 128) 0.4141 (0.3321–0.5011) 0.0156 (0.0039–0.0603) 0.0938 (0.0540–0.1578) 0.5625 (0.4755–0.6458) 0.1719 (0.1159–0.2473) 0.3594 (0.2811–0.4460) 0.2188 (0.1555–0.2986) 0.5234 (0.4371–0.6084)

Dose 1 (subgroups by age, n = 23,479)

16 to 55 years old (n = 16,177) 0.8000 (0.6778–0.8838) 0.0649 (0.0612–0.0688) 0.0458 (0.0094–0.1949) 0.5272 (0.3499–0.6979) 0.1615 (0.0842–0.2875) 0.2984 (0.1765–0.4578) 0.1733 (0.1043–0.2739) 0.4549 (0.3267–0.5892)
Over 55 years old (n = 7,302) 0.5935 (0.3553–0.7945) 0.0525 (0.0374–0.0731) 0.0049 (0.0019–0.0123) 0.3373 (0.3265–0.3482) 0.0568 (0.0518–0.0624) 0.1805 (0.1388–0.2313) 0.1275 (0.0897–0.1782) 0.2919 (0.2130–0.3857)

Dose 1 ≥ grade 3 (subgroups by vaccine type, n = 23,505)

Protein subunit 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000
(n = 26) (0.0000– 1.0000) (0.0000– 1.0000) (0.0000– 1.0000) (0.0000–1.0000) (0.0000–1.0000) (0.0000–1.0000) (0.0000–1.0000) (0.0000–1.0000)
RNA-based vaccine 0.0138 0.0065 0.0022 0.0104 0.0030 0.0064 0.0048 0.0142
(n = 23,351) (0.0052– 0.0361) (0.0049–0.0086) (0.0007– 0.0063) (0.0092– 0.0118) (0.0012– 0.0074) (0.0054–0.0075) (0.0037–0.0062) (0.0101–0.0199)
Viral vector (non-replicating) 0.0000 0.0000 0.0078 0.0313 0.0234 0.0156 0.0078 0.0156
(n = 128) (0.0000– 1.0000) (0.0000–1.0000) (0.0011–0.0533) (0.0118– 0.0803) (0.0076–0.0701) (0.0039–0.0603) (0.0011–0.0533) (0.0039–0.0603)

RNA-based vaccine dose 1 (subgroups by age, n = 23,351)

16 to 55 years old (n = 16,128) 0.8507 (0.8219–0.8755) 0.0647 (0.0596–0.0702) 0.0193 (0.0069–0.0528) 0.4263 (0.3682–0.4865) 0.1137 (0.0847–0.1510) 0.2239 (0.2060–0.2429) 0.1358 (0.1014–0.1796) 0.3857 (0.3406–0.4328)
Over 55 years old (n = 7,223) 0.7250 (0.704–0.7451) 0.0555 (0.0401–0.0765) 0.0053 (0.0021–0.0135) 0.3361 (0.3253–0.3471) 0.0568 (0.0517–0.0623) 0.1669 (0.1310–0.2103) 0.1224 (0.0796–0.1836) 0.2473 (0.2375–0.2573)

Dose 2 (subgroups by vaccine type, n = 32,805)

Inactivated vaccine (n = 6,286) 0.3175 (0.0781–0.7188) 0.0576 (0.0521–0.0636) 0.0060 (0.0007–0.0515) 0.0533 (0.0072–0.3041) 0.0161 (0.0008–0.2528) 0.0152 (0.0002–0.5744) 0.0156 (0.0006–0.2925) 0.0778 (0.0050–0.5877)
Protein subunit (n = 26) 0.5769 (0.3851–0.7480) 0.0385 (0.0054–0.2279) 0.0000 (0.0000–1.0000) 0.4615 (0.2839–0.6495) 0.0000 (0.0000–1.0000) 0.4615 (0.2839–0.6495) 0.2692 (0.1341–0.4671) 0.4615 (0.2839–0.6495)
RNA-based vaccine (n = 22,860) 0.8176 (0.6887–0.9009) 0.0890 (0.0565–0.1374) 0.1473 (0.1364–0.1590) 0.6057 (0.5369–0.6705) 0.3677 (0.2750–0.4713) 0.4553 (0.2945–0.6260) 0.3069 (0.1760–0.4785) 0.5260 (0.4418–0.6088)
Viral vector (non-replicating; n = 3,633) 0.4475 (0.3455–0.5540) 0.0534 (0.0465–0.0612) 0.1796 (0.0007–0.9846) 0.3922 (0.3765–0.4082) 0.0020 (0.0000–0.2194) 0.2622 (0.1949–0.3429) 0.0197 (0.0005–0.4453) 0.3473 (0.2742–0.4283)

Dose 2 (subgroups by age, n = 26,344)

16 to 55 years old (n = 17,988) 0.7240 (0.5312–0.8586) 0.0699 (0.0413–0.1158) 0.1160 (0.0499–0.2471) 0.5681 (0.4737–0.6577) 0.0440 (0.0008–0.7399) 0.4368 (0.3307–0.5490) 0.0295 (0.0006–0.6011) 0.4901 (0.3842–0.5969)
Over 55 years old (n = 8,356) 0.5106 (0.2473–0.7682) 0.0528 (0.0279–0.0975) 0.0478 (0.0167–0.1291) 0.4367 (0.3235–0.5569) 0.0291 (0.0010–0.4605) 0.2992 (0.2108–0.4055) 0.0396 (0.0014–0.5424) 0.3600 (0.2885–0.4384)

Dose 2 ≥ grade 3 (subgroups by vaccine type, n = 32,592)

Inactivated virus 0.0000 0.0000 0.0000 0.0000 0.0001 0.0000 0.0001 0.0000
(n = 6,202) (0.0000–1.0000) (0.0000–1.0000) (0.0000– 1.0000) (0.0000–1.0000) (0.0000– 0.0013) (0.0000–1.0000) (0.0000– 0.0013) (0.0000– 1.0000)
Protein subunit 0.0000 0.0000 0.0000 0.0385 0.0189 0.0385 0.0385 0.0000
(n = 26) (0.0000– 1.0000) (0.0000–1.0000) (0.0000–1.0000) (0.0054– 0.2279) (0.0012–0.2938) (0.0054–0.2279) (0.0056–0.2628) (0.0000– 1.0000)
RNA-based vaccine 0.0212 0.0072 0.0135 0.0634 0.0164 0.0425 0.0245 0.0344
(n = 22,860) (0.0083–0.0533) (0.0021– 0.0248) (0.0117– 0.0156) (0.0343– 0.1145) (0.0104–0.0258) (0.0144– 0.1188) (0.0055– 0.1097) (0.0235– 0.0501)
Viral vector (non-replicating) 0.0031 0.0017 0.0023 0.0103 0.0024 0.0094 0.0024 0.0071
(n = 3,504) (0.0017–0.0057) (0.0008– 0.0038) (0.0011–0.0046) (0.0074– 0.0142) (0.0001–0.0452) (0.0067–0.0132) (0.0001– 0.0452) (0.0048– 0.0105)

RNA-based vaccine dose 2 (subgroups by age, n = 22,860)

16 to 55 years old (n = 15,707) 0.8488 (0.7482–0.9138) 0.0879 (0.0517–0.1454) 0.1681 (0.1588–0.1778) 0.6346 (0.5728–0.6922) 0.4168 (0.3259–0.5136) 0.4928 (0.3261–0.6611) 0.3267 (0.1863–0.5069) 0.5751 (0.4988–0.6480)
Over 55 years old (n = 7,153) 0.7557 (0.6183–0.8553) 0.0874 (0.0642–0.1179) 0.1050 (0.0981–0.1123) 0.5467 (0.4958–0.5967) 0.2678 (0.2166–0.3261) 0.3763 (0.2602–0.5087) 0.2622 (0.1667–0.3870) 0.4255 (0.3768–0.4757)

Viral vector vaccine dose 2 (subgroups by age, n = 3,484)

16 to 55 years old 0.5831 0.0299 0.0257 0.4419 0.0010 0.3906 0.0008 0.4445
(n = 2,281) (0.5627–0.6032) (0.0019–0.3302) (0.0006– 0.5449) (0.4216– 0.4624) (0.0000– 0.9134) (0.3708–0.4108) (0.0000–0.6305) (0.4243– 0.4650)
over 55 years old 0.2736 0.0266 0.0291 0.3009 0.0013 0.2377 0.0017 0.3026
(n = 1,203) (0.1816– 0.3898) (0.0189– 0.0374) (0.0210– 0.0403) (0.2756– 0.3274) (0.0000– 0.3578) (0.2145– 0.2626) (0.0000– 0.8062) (0.2773– 0.3291)
HHS Vulnerability Disclosure